Lirias: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
As compared with tamoxifen, letrozole significantly reduced the risk of an event ending a period of disease-free survival ( ... hazard ratio, 0.81; 95 percent confidence interval, 0.70 to 0.93; P=0.003), especially the risk of distant recurrence (hazard ... with five-year disease-free survival estimates of 84.0 percent and 81.4 percent, respectively. ... BACKGROUND: The aromatase inhibitor letrozole is a more effective treatment for metastatic breast cancer and more effective in ...https://lirias.kuleuven.be/handle/123456789/34763
Calcitriol restores antiestrogen responsiveness in estrogen receptor negative breast cancer cells: A potential new therapeutic...
... since a long-term use of this compound increases disease-free survival and reduces tumor recurrence [6, 7]. Unfortunately, up ... In breast cancer, the presence of the ERα is considered as a good indicator of disease-free survival and prognosis since ... Estrogen receptorBreast cancerHormonal therapyCalcitriolVDR. Background. Breast cancer is a heterogeneous disease, encompassing ... while VDR-positive breast cancer patients had significantly longer disease-free survival than those with VDR-negative tumors [ ...https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-14-230
Molecular Cytogenetic Identification of Subgroups of Grade III Invasive Ductal Breast Carcinomas with Different Clinical...
A and C, disease-free survival; B and D, overall survival. A and B, cluster 1 tumors plotted against all others; C and D, CK14- ... Elston CW, Ellis IO Pathological prognostic factors in breast cancer.: I. The value of histological grade in breast cancer: ... differentiated grade III invasive ductal carcinomas are strongly associated with shorter recurrence-free and overall survival ... CK14 positivity showed no significant influence on prognosis in this cohort (disease-free survival P = 0.193; overall survival ...http://clincancerres.aacrjournals.org/content/10/18/5988.long
Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells | SpringerLink
Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res 10( ... an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer ... little is known about its possible role in breast cancer. We have investigated the role of AR expression in human breast cancer ... Lea OA, Kvinnsland S, Thorsen T (1989) Improved measurement of androgen receptors in human breast cancer. Cancer Res 49(24 Pt 1 ...https://link.springer.com/article/10.1007%2Fs10549-009-0436-8
An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer |...
... for UPP end-point was disease-specific survival, and for JRH-2 it was recurrence-free survival), with the number of events and ... breast cancer. (b) Overall survival for ER- breast cancer. (c) Time to distant metastasis for ER+ breast cancer. (d) Time to ... Although ER-negative disease has overall worse prognosis than does ER-positive breast cancer, not all ER-negative breast cancer ... for UPP the end-point was disease-specific survival, and for JRH-2 it was recurrence-free survival), with the number of events ...https://genomebiology.biomedcentral.com/articles/10.1186/gb-2007-8-8-r157
Endoxifen in Adults With Hormone Receptor Positive Solid Tumors - Full Text View - ClinicalTrials.gov
These factors are associated with a higher rate of recurrence and shorter disease-free survival in breast cancer patients ... Gynecologic Cancer. Breast Cancer. Desmoid Tumor. Endometrial Cancer. Ovarian Cancer. Uterine Cancer. Fallopian Tube Cancer. ... These factors are associated with a higher rate of recurrence and shorter disease-free survival in breast cancer patients ... Patients with breast cancer must have had at least one prior chemotherapy regimen for metastatic disease. Additionally, ...https://clinicaltrials.gov/ct2/show/NCT01273168?term=desmoid+tumor
AIB1:ERα Transcriptional Activity Is Selectively Enhanced in Aromatase Inhibitor-Resistant Breast Cancer Cells | Clinical...
AIB1 significantly associated with disease recurrence and reduced disease-free survival in AI-resistant breast cancer. One of ... AIB1 associates with poor disease-free survival in AI-treated breast cancer. Strong nuclear expression of AIB1 was observed in ... B, Kaplan-Meier estimates of disease-free survival of patients with breast cancer according to AIB1 status in tamoxifen (n = ... AIB1 associates with poor disease-free survival in AI-treated breast cancer. A, immunohistochemical localization of AIB1 (×100 ...http://clincancerres.aacrjournals.org/content/18/12/3305
www.patientcenters.com -- Breast Cancer Center
The endpoints (measured outcomes) of the trial are disease-free survival and safety, as well as distant recurrence and survival ... After Breast Cancer, by Musa Mayer: Upcoming March 28, 2003 Report Back from the 25th San Antonio Breast Cancer Symposium. By ... More impressive still was the reduction in risk of recurrence in contralateral breast cancer (a new primary cancer in the other ... There was no difference in disease-free survival or overall survival with the sequential vs. combination regimens. In addition ...http://www.oreilly.com/medical/breastcancer/news/2003_research.html
Xeloda(R), Taxotere(R) and Herceptin(R) Combination Study Suggests Clinical Benefit in Invasive Breast Cancer with Shortened...
Breast,Cancer,with,Shortened,Treatment,Cycle,medicine,medical news today,latest medical news,medical newsletters,current ... Secondary endpoints included safety profile; quality of life; local recurrence; disease-free survival; distant disease-free ... Breast cancer is the most common cancer among women, other than skin cancer. It is the second leading cause of cancer death in ... Invasive breast cancer, also known as infiltrating breast cancer, is cancer that has spread to surrounding, healthy tissue. ...http://www.bio-medicine.org/medicine-news-1/Xeloda-28R-29--Taxotere-28R-29-and-Herceptin-28R-29-Combination-Study-Suggests-Clinical-Benefit-in-Invasive-Breast-Cancer-with-Shortened-Treatment-Cyc-8338-1/
Prognostic and Clinical Significance of miRNA-205 in Endometrioid Endometrial Cancer
... survival rate, recurrence rate, staging, myometrial invasion, grading and lymph nodes involvement. Higher levels of miRNA-205 ... MiRNA-205 seems to be one of the key regulators of gene expression in endometrial cancer. In this study, we investigated ... Kaplan-Maier analysis revealed that higher levels of miRNA-205 were associated with better overall survival (p = 0,034). These ... Despite the relatively favourable prognosis in cases of endometrial cancer, there is a necessity to evaluate clinical and ...http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0164687
Risk of Breast Cancer Recurrence Associated with Carbohydrate Intake and Tissue Expression of IGFI Receptor | Cancer...
1: HR 2.3; 95% CI, 1.4-3.9 for distant disease-free survival; ref. 30). The authors concluded that insulin-related factors may ... Breast cancer recurrence by IGFI receptor status and carbohydrate intake among postmenopausal breast cancer survivors in a ... and breast cancer recurrence. The hypothesis was tested in a nested case-control analysis of postmenopausal breast cancer ... Breast cancer recurrence cases (91) were matched to two controls (n = 174) on disease and study characteristics and counter ...http://cebp.aacrjournals.org/content/23/7/1273?rss=1
Obese breast ca patients carry greater recurrence risk | Cancer Network | The Oncology Journal
A 30-year study of nearly 20,000 Danish women made a defensible connection between obesity and poor prognosis after breast ... The influence of BMI on cause-specific survival and invasive disease-free survival were analyzed. ... The results confirm...that there is an independent, increased risk of breast cancer death for heavy women with breast cancer," ... Study advances link between obesity, breast cancer mortality The advantages of the Danish study included the large patient ...http://www.cancernetwork.com/articles/obese-breast-ca-patients-carry-greater-recurrence-risk
Ijzerman, M. J.<...
Survival after locoregional recurrence or second primary breast cancer: Effect of the disease-free interval. Jeeninga-Witteveen ... Comparison of Logistic Regression and Bayesian Networks for Risk Prediction of Breast Cancer Recurrence. Witteveen, A., Nane, G ... Evidence on the cost of breast cancer drugs is required for rational decision making. Berghuis, A. M. S., Koffijberg, H., ...https://research.utwente.nl/en/persons/maarten-j-ijzerman
Accelerated Partial Breast Irradiation for Early Breast Cancer - Full Text View - ClinicalTrials.gov
To determine the time to ipsilateral breast recurrence, disease free survival and overall survival of women with node-negative ... time to ipsilateral breast recurrence, disease-free survival, and overall survival. ... Disease free survival [ Time Frame: First analysis will occur 5 years after accrual of all patients (approximately 6 years ... Breast Cancer Radiation: Accelerated partial breast irradiation (APBI) to region of tumour bed using 3D conformal radiation ...https://clinicaltrials.gov/ct2/show/NCT00418210
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence - Full Text View -...
To evaluate and compare the disease free survival (DFS) in the vaccinated and control subjects. ... Breast Neoplasms. Recurrence. Neoplasms by Site. Neoplasms. Breast Diseases. Skin Diseases. Disease Attributes. Pathologic ... Patterns of recurrence to include Time to recurrence (TTR), time to local recurrence (TTLR), time to distant recurrence (TTDR ... vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group ...https://clinicaltrials.gov/ct2/show/study/NCT01479244?term=galena&rank=1&show_locs=Y
Incidence and prognosis in early onset breast cancer
Disease-free interval and survival in patients with distant recurrence were strongly associated to histologic grade and hormone ... 1. Prognostic Factors in Breast Cancer. Open this publication in new window or tab ,,Prognostic Factors in Breast Cancer. ... Histologic grade was strongly correlated to breast cancer mortality in 630 patients with primary breast cancer. The combination ... The incidence of early onset breast cancer has increased moderately and the survival rate has not improved during the last 35 ...http://liu.diva-portal.org/smash/record.jsf?pid=diva2:248721
Obesity Linked to Worse Outcomes in Early Breast Cancer Treatment - Healthcanal.com : Healthcanal.com
Obesity was linked to shorter time to recurrence (TTR), disease-free survival (DFS) and overall survival (OS). The exception ... facilitating the rapid translation of new knowledge into better care for patients with breast cancer. The Cancer Therapy & ... "Obesity is a probable risk factor for worse breast cancer outcomes, and ours is the latest study to suggest it has an effect on ... The mission of the CTRC-AACR San Antonio Breast Cancer Symposium is to produce a unique and comprehensive scientific meeting ...https://www.healthcanal.com/cancers/24307-obesity-linked-to-worse-outcomes-in-early-breast-cancer-treatment.html
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing...
Recurrence Rate at 3 years [ Time Frame: 3 years after completion of standard chemotherapy and surgery ]. Rate for patients ... Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing ... II Randomized Trial Evaluating the Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer ... Breast Neoplasms. Neoplasms by Site. Neoplasms. Breast Diseases. Skin Diseases. Paclitaxel. Docetaxel. Liposomal doxorubicin. ...https://clinicaltrials.gov/ct2/show/NCT01779050
Breast Cancer Survival Improves Herceptin Used With Chemotherapy - Redorbit
... and found that five-year disease-free survival (defined as no cancer recurrence) was increased from 72 percent (Arm A) to 80 ... North Central Cancer Treatment Group (NCCTG) Breast Committee and a breast cancer researcher at the Mayo Clinic campus in ... Their five-year disease-free-survival increased to 84 percent, compared to 80 percent in Arm B. ... "The study demonstrated that adding Herceptin clearly improves disease-free survival, with improvement if given after ...http://www.redorbit.com/news/health/1798608/breast_cancer_survival_improves_herceptin_used_with_chemotherapy/
Zoledronic Acid May Help Reduce Breast Cancer Progression | Medpage Today
... hormone-responsive breast cancer, bisphosphonate therapy during adjuvant endocrine treatment may improve disease-free survival ... No effect on disease-free survival (hazard ratio 1.10, P=0.59) *No impact on recurrence-free survival (HR 1.11, P=0.53) *No ... Improved recurrence-free survival at 47.8 months (94.0% versus 90.9%, P=0.01) *A 35% reduction in risk of recurrence (P=0.02) * ... Improved disease-free survival rates (94.0% versus 90.8%, P=0.01) *A 36% relative reduction in risk of disease progression (P= ...https://www.medpagetoday.com/endocrinology/osteoporosis/12853
High-Dose Chemotherapy With Stem-Cell Transplantation Offers Little Benefit for Women With Breast Cancer
... and time to recurrence. In this study, disease-free survival meant the women were alive and without breast cancer relapse or a ... Relapse-free survival meant the women were alive and without a breast cancer relapse at their last follow-up visit. Overall ... The researchers followed the women for about six years then calculated their disease-free survival, overall survival, ... After a breast cancer has been removed, chemotherapy is often the method of choice for preventing recurrence. Chemotherapy is ...http://www.empowher.com/media/reference/high-dose-chemotherapy-stem-cell-transplantation-offers-little-benefit-wome
Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy | Breast Cancer Research | Full...
... we report 10-year annual hazards of recurrence in HER2+ patients not treated with anti-HER2 therapy. Disease-free survival (DFS ... disease (hazard ratio 0.72, P = 0.02). This difference was explainable by a significantly higher hazard of recurrence in years ... Hazards of recurrence of these patients with respect to hormone receptor status of the primary tumor have not been described. ... The high early risk of recurrence of HER2+ HR- patients declined sharply over time, so that it was similar to that seen in ...https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-015-0568-1
Web Cast of Landmark, Independent Trial Data from Major Breast Cancer Meeting | Medienmitteilung IBCSG
Gallen, Switzerland (ots/PRNewswire) - - Promising News for Breast Cancer Patients - Web Cast Briefing Available at http://www. ... Letrozole significantly prolonged disease free survival. compared with tamoxifen. - Letrozole reduced the risk of breast cancer ... Letrozole Reduces the Risk of Post-Surgery Recurrence of Early Breast Cancer When Compared With Tamoxifen, Study Shows. St. ... In postmenopausal women with early breast cancer, letrozole offers better post-surgery protection against breast cancer ...https://www.presseportal.ch/de/pm/100007129/100485390
Improved methods of detection, and prognostic significance, of vascular invasion in breast cancer. | Cancer Research
... recurrence and worse disease free interval (DFI) and overall survival (OS). In multivariate analysis, LVI was an independent ... Cancer Research Online ISSN: 1538-7445. Cancer Research Print ISSN: 0008-5472. Journal of Cancer Research ISSN: 0099-7013. ... Improved methods of detection, and prognostic significance, of vascular invasion in breast cancer.. RA Mohammed, IO Ellis, AR ... There was no significant difference between the frequency of LVI and development of recurrence or death from the disease.. ...http://cancerres.aacrjournals.org/content/69/2_Supplement/3010
Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer...
Disease Free Survival (DFS) [ Time Frame: Time from randomization through 5 years ]. Breast cancer recurrence, second primary ... Breast Neoplasms. Neoplasms by Site. Neoplasms. Breast Diseases. Skin Diseases. Paclitaxel. Liposomal doxorubicin. Albumin- ... node-positive breast cancer that overexpresses HER2.. *Compare the effect of these regimens on disease-free and overall ... Jahanzeb M. Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin Breast Cancer. 2008 Aug;8(4):324-33. doi: ...https://clinicaltrials.gov/show/NCT00004067